stockrowAtara Biotherapeutics, Inc.
ATRA Healthcare Biotechnology
Atara Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $120.8 million, down 6.33% from fiscal 2024.
- Revenue
- −96.4%
- EPS
- −260.0%
- Free cash flow
- +52.1%
Quarter to June 2026, against a year earlier
Follow ATRA
Alert me
Atara Biotherapeutics, Inc. (ATRA) EV/Sales
As of 6 November 2026, Atara Biotherapeutics, Inc. (ATRA) trades at a EV/Sales of 17.7×. Over the past ten years it has ranged from −17.2× (November 2023) to 59.5× (January 2022); the current reading is higher than 94% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.8× | 309.02% |
| FY2024 | 0.4× | — |
| FY2023 | −0.1× | — |
| FY2022 | 1.4× | (97.35%) |
| FY2021 | 54.3× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 26.3× | 943.59% |
| Mar 2026 | 2.5× | 39.17% |
| Dec 2025 | 1.8× | 52.11% |
| Sep 2025 | 1.2× | 212.26% |
| 18 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TNXP Tonix Pharmaceuticals Holding Corp. compare | −3.1× |
| RLYB Rallybio Corporation compare | −0.8× |
| KZIA Novogen Limited compare | n/m |
| TLSA Tiziana Life Sciences Ltd compare | n/m |
| CLLS Cellectis S.A. compare | 0.2× |
| EQ Equillium, Inc. compare | 2.9× |
| GNLX Genelux Corporation compare | 7.0× |
| NRXS Neuraxis, Inc. compare | 12.8× |
| ATRA Atara Biotherapeutics, Inc. | 17.7× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)